Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Abstract

Ten patients suffering from advanced myotonic dystrophy with severe myotonic symptoms were treated with 800-1200 mg/day of the anti-arrhythmic drug tocainide (Xylotocan). All patients reported a marked subjective improvement of myotonia, which was confirmed by objective tests. Except for a slight QT-prolongation in one patient, the ECG was not significantly altered by the treatment. Twenty-four-hour ECG after treatment disclosed that pre-existing ventricular arrhythmia disappeared in three cases. The occurrence of complex ventricular arrhythmia in two patients under treatment was not necessarily due to specific effects of the drug but might be explained by the high spontaneous variability of rhythm disorders. In these patients suffering from myotonic dystrophy with typical cardiomyopathy no deleterious effects of the drug were observed, especially no cardiac arrhythmias which would have necessitated interruption of treatment. Therefore, the authors recommend symptomatic therapy with tocainide for myotonia and paramyotonia congenita, as well as in myotonic dystrophy patients suffering from marked myotonic stiffness. ECG and 24-h ECG should be carefully recorded as necessary in any treatment with anti-arrhythmic drugs.

• Authors: U Mielke, A Haass, S Sen, W Schmidt
• Journal: Journal of neurology (J Neurol) Vol. 232 Issue 5 Pg. 271-4 ( 1985) ISSN: 0340-5354 [Print] Germany
• PMID: 3932602 (Publication Type: Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Tocainide
• Lidocaine

Topics

• Adult
• Anti-Arrhythmia Agents (adverse effects, therapeutic use)
• Arrhythmias, Cardiac (complications, drug therapy)
• Electrocardiography
• Female
• Humans
• Lidocaine (adverse effects, analogs & derivatives, therapeutic use)
• Male
• Middle Aged
• Monitoring, Physiologic
• Myotonic Dystrophy (complications, drug therapy)
• Syndrome
• Tocainide